Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Numinus Wellness gets Health Canada approval for open-label study for MDMA-Assisted Therapy for PTSD

Numinus Wellness gets Health Canada approval for open-label study for MDMA-Assisted Therapy for PTSD

Numinus Wellness Medical and Therapeutic Services Director for Numinus Dr. Devon Christie joined Steve Darling from Proactive to announce Health Canada has cleared an open-label safety and feasibility study evaluating MDMA-assisted therapy for post-traumatic stress disorder.

Dr Christie, who will serve as the study’s Qualified Investigator, tells Proactive during the study, research, medical and therapist staff at Numinus will collect data on the safety and effectiveness of MDMA-assisted therapy and then inform Health Canada.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK